Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research and development.
We have two parallel objectives: improve patient access to medicines and foster economic growth in the region.
Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the…
Sub-Saharan Africa might not be considered among the top destinations for the global pharmaceutical industry, but Shalina Healthcare considers it home and has established itself as the leading pharma company…
Ronald Boueri of Zimmer Biomet Middle East discusses the challenges of establishing the business, the importance of providing the latest innovation and assistance to medical professionals in the MENA (Middle…
The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma…
Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and…
The latest Middle East and North Africa (MENA) pharma, including Egypt’s opening of the largest “pharmaceutical city” in the Middle East and Abu Dhabi’s quest to become a pharma hub…
See our Cookie Privacy Policy Here